Patient-Friendly Explanation

Efpeglenatide is an investigational once-weekly injection from the same family of medicines as semaglutide, known as GLP-1 receptor agonists. It works by reducing appetite and slowing stomach emptying to help you feel full for longer. It is being studied for both type 2 diabetes and obesity.

Clinical Definition

Efpeglenatide is a long-acting, exendin-4-based GLP-1 receptor agonist delivered by once-weekly subcutaneous injection. It lowers blood glucose and body weight by enhancing glucose-dependent insulin secretion, suppressing glucagon and delaying gastric emptying. Phase 3 trials have demonstrated meaningful weight reduction and cardiovascular benefit, supporting its potential role in obesity pharmacotherapy.

Why It Matters

GLP-1 receptor agonists have transformed medical weight management, and longer-acting options such as efpeglenatide may improve convenience and adherence. NuLifeCare Singapore already uses this class of medication, and our doctors can help patients choose the most suitable option.